IL217942A0 - Intravenous formulations of neurokinin-1 antagonist - Google Patents

Intravenous formulations of neurokinin-1 antagonist

Info

Publication number
IL217942A0
IL217942A0 IL217942A IL21794212A IL217942A0 IL 217942 A0 IL217942 A0 IL 217942A0 IL 217942 A IL217942 A IL 217942A IL 21794212 A IL21794212 A IL 21794212A IL 217942 A0 IL217942 A0 IL 217942A0
Authority
IL
Israel
Prior art keywords
neurokinin
antagonist
intravenous formulations
intravenous
formulations
Prior art date
Application number
IL217942A
Other languages
English (en)
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of IL217942A0 publication Critical patent/IL217942A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL217942A 2009-08-14 2012-02-05 Intravenous formulations of neurokinin-1 antagonist IL217942A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23412909P 2009-08-14 2009-08-14
PCT/US2010/045317 WO2011019911A1 (en) 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists

Publications (1)

Publication Number Publication Date
IL217942A0 true IL217942A0 (en) 2012-03-29

Family

ID=43586486

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217942A IL217942A0 (en) 2009-08-14 2012-02-05 Intravenous formulations of neurokinin-1 antagonist

Country Status (15)

Country Link
US (2) US9101615B2 (cg-RX-API-DMAC7.html)
EP (2) EP2464230B1 (cg-RX-API-DMAC7.html)
JP (2) JP5860399B2 (cg-RX-API-DMAC7.html)
KR (1) KR101834577B1 (cg-RX-API-DMAC7.html)
CN (2) CN102573475B (cg-RX-API-DMAC7.html)
AU (1) AU2010282483B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012003263A2 (cg-RX-API-DMAC7.html)
CA (1) CA2770403C (cg-RX-API-DMAC7.html)
ES (1) ES2609640T3 (cg-RX-API-DMAC7.html)
IL (1) IL217942A0 (cg-RX-API-DMAC7.html)
MX (1) MX336071B (cg-RX-API-DMAC7.html)
RU (2) RU2017145628A (cg-RX-API-DMAC7.html)
SG (2) SG178403A1 (cg-RX-API-DMAC7.html)
TW (2) TW201604195A (cg-RX-API-DMAC7.html)
WO (1) WO2011019911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170838A1 (en) 2006-04-05 2011-05-30 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}- methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
US7563801B2 (en) 2006-04-05 2009-07-21 Schering Corporation Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
CA2736195C (en) 2008-09-05 2017-05-16 Opko Health, Inc. Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
MX336071B (es) 2009-08-14 2016-01-06 Opko Health Inc Formulaciones intravenosas de antagonistas de neurocinina 1.
AR097683A1 (es) * 2013-09-26 2016-04-06 Lilly Co Eli Compuestos y uso para la preparación de agentes de formación de imagen tau y formulaciones para la formación de imagen tau
JP6741655B2 (ja) 2014-09-19 2020-08-19 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アプレピタントのエマルジョン製剤
DK3265087T3 (da) 2015-03-04 2020-10-19 Vanda Pharmaceuticals Inc Fremgangsmåde til behandling med tradipitant
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CA3013288A1 (en) * 2016-02-01 2017-08-10 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
US9974742B2 (en) * 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
EP3493815B1 (en) * 2016-08-03 2022-02-16 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
CN109963583B (zh) * 2016-11-21 2023-06-09 珠海贝海生物技术有限公司 罗拉吡坦制剂
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
WO2019005830A1 (en) 2017-06-26 2019-01-03 Fordoz Pharma Corp. NANOSOME FORMULATIONS OF APREPITANT AND METHODS AND APPLICATIONS THEREOF
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
CN108703950B (zh) * 2018-08-27 2021-04-20 辅必成（上海）医药科技有限公司 一种罗拉吡坦的乳剂注射液
CN109394693A (zh) * 2018-12-25 2019-03-01 广州白云山汉方现代药业有限公司 一种罗拉匹坦乳剂及其制备方法和应用
CN109453115A (zh) * 2018-12-25 2019-03-12 广州白云山汉方现代药业有限公司 一种罗拉匹坦静脉注射乳剂及其制备方法和应用
BR112021026554A2 (pt) 2019-06-28 2022-05-24 Jiangsu Hengrui Medicine Co Antagonista de neurocinina-1
KR20220165251A (ko) 2020-04-03 2022-12-14 네르 쎄라퓨틱스 리미티드 패혈증, 패혈성 쇼크, 급성 호흡 곤란 증후군 (ards) 또는 다발성 기관 기능장애 증후군 (mods)으로부터 선택된 질환을 치료하기 위한 nk-1 수용체 길항제
CA3177477A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
KR20230127252A (ko) * 2020-12-25 2023-08-31 상하이 쉥디 파마슈티컬 컴퍼니 리미티드 5-ht3 수용체 길항제와 조합된 nk1 길항제 전구약물화합물의 용도
WO2023134725A1 (zh) * 2022-01-12 2023-07-20 江苏恒瑞医药股份有限公司 一种包含神经激肽-1拮抗剂前药化合物的药物组合物
WO2023134723A1 (zh) * 2022-01-12 2023-07-20 江苏恒瑞医药股份有限公司 一种神经激肽-1拮抗剂前药化合物的晶型
CN119528985A (zh) * 2023-08-28 2025-02-28 科睿迪(南京)医药科技有限公司 神经激肽-1受体拮抗剂化合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338372A3 (en) * 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
JP3350048B2 (ja) * 1989-07-07 2002-11-25 アンドルシェルシュ・インコーポレイテッド アンドロゲン関連疾患の治療方法
US5610140A (en) * 1991-04-01 1997-03-11 Cortech, Inc. Bradykinin receptor antagonists with neurokinin receptor blocking activity
EP0666856B1 (en) 1992-10-28 2000-01-05 MERCK SHARP & DOHME LTD. 4-arylmethyloxymethyl piperidines as tachykinin antagonists
CA2150951A1 (en) 1992-12-14 1994-06-23 Angus Murray Macleod 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
ES2120170T3 (es) 1994-01-13 1998-10-16 Merck Sharp & Dohme Antagonistas azaciclicos gem-disustituidos de taquiquininas.
PT812195E (pt) 1995-02-28 2003-03-31 Aventis Pharma Inc Composicao farmaceutica para compostos de piperidinoalcanol
SE9503143D0 (sv) * 1995-09-12 1995-09-12 Astra Ab New preparation
GB9601680D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
WO1998002158A1 (en) 1996-07-17 1998-01-22 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
US6162805A (en) 1997-04-24 2000-12-19 Merck Sharp & Dohme Limited Use of an NK-1 receptor antagonist and an SSRI for treating obesity
JP3571511B2 (ja) * 1997-11-11 2004-09-29 トーアエイヨー株式会社 経皮吸収製剤
AU779073B2 (en) * 1998-12-23 2005-01-06 Nps Allelix Corp. Indole and indolizidine derivatives for the treatment of migraine
MXPA01011981A (es) 1999-05-24 2003-09-04 Sonus Pharma Inc Vehiculo de emulsion para farmacos poco solubles.
US6436928B1 (en) 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
EP1237874B1 (en) 1999-12-17 2006-02-22 Schering Corporation Selective neurokinin antagonists
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
MY128449A (en) * 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1368322A4 (en) * 2001-02-12 2004-03-17 Teva Pharma NOVEL CRYSTALLINE FACIES OF OXCARBAZEPINE AND PROCESSES FOR THEIR PREPARATION
ES2291538T3 (es) 2001-11-13 2008-03-01 Schering Corporation Antagonistas de nk1.
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
ATE358482T1 (de) * 2002-07-03 2007-04-15 Schering Corp 1-amido-4-phenyl-4-benzyloxymethyl-piperidin derivative und verwandte verbindungen als neurokinin-1 (nk-1) antagonsisten zur behandlung von erbrechen, depressionen, angstzustände und husten
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
CA2518836A1 (en) 2003-03-13 2004-09-30 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
GB0321256D0 (en) * 2003-09-11 2003-10-08 Generics Uk Ltd Novel crystalline compounds
US7309790B2 (en) 2003-10-03 2007-12-18 Pfizer Inc Chemical compounds
JP2007515425A (ja) * 2003-12-22 2007-06-14 シェーリング　コーポレイション 医薬組成物
CN101006074B (zh) * 2004-07-01 2012-02-15 欧科生医股份有限公司 作为nk1拮抗剂的哌啶衍生物
US7871632B2 (en) * 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
WO2006060580A1 (en) * 2004-11-30 2006-06-08 Myriad Genetics, Inc. Therapeutic formulations
CN100367951C (zh) * 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
US20070207201A1 (en) * 2006-03-06 2007-09-06 Wyeth Liquid and Semi-Solid Pharmaceutical Formulations and Processes
US7563801B2 (en) * 2006-04-05 2009-07-21 Schering Corporation Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
SG170838A1 (en) 2006-04-05 2011-05-30 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}- methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
CN101110758A (zh) 2006-07-21 2008-01-23 华为技术有限公司 建立紧急会话的方法、系统及代理呼叫会话控制功能
TWI426073B (zh) * 2006-08-07 2014-02-11 Palau Pharma Sa 抗黴菌組合物
EP2125802A4 (en) * 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AR066191A1 (es) * 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
CA2736195C (en) 2008-09-05 2017-05-16 Opko Health, Inc. Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
MX336071B (es) 2009-08-14 2016-01-06 Opko Health Inc Formulaciones intravenosas de antagonistas de neurocinina 1.

Also Published As

Publication number Publication date
RU2642234C2 (ru) 2018-01-24
KR101834577B1 (ko) 2018-03-05
BR112012003263A2 (pt) 2015-09-22
WO2011019911A1 (en) 2011-02-17
EP2464230A1 (en) 2012-06-20
JP2013501806A (ja) 2013-01-17
TWI498329B (zh) 2015-09-01
KR20120060215A (ko) 2012-06-11
CN102573475B (zh) 2016-01-20
US20110038925A1 (en) 2011-02-17
JP6308991B2 (ja) 2018-04-11
CA2770403C (en) 2020-09-01
MX2012001872A (es) 2012-04-11
TW201604195A (zh) 2016-02-01
CN105503870A (zh) 2016-04-20
SG10201407538WA (en) 2015-01-29
TW201111382A (en) 2011-04-01
CA2770403A1 (en) 2011-02-17
ES2609640T3 (es) 2017-04-21
RU2012109405A (ru) 2013-09-20
JP2016041734A (ja) 2016-03-31
CN102573475A (zh) 2012-07-11
JP5860399B2 (ja) 2016-02-16
EP3143996A1 (en) 2017-03-22
EP2464230B1 (en) 2016-10-05
AU2010282483A1 (en) 2012-03-01
SG178403A1 (en) 2012-03-29
AU2010282483B2 (en) 2014-09-04
US20160024092A1 (en) 2016-01-28
RU2017145628A (ru) 2019-02-19
EP2464230A4 (en) 2013-01-02
US9101615B2 (en) 2015-08-11
MX336071B (es) 2016-01-06

Similar Documents

Publication Publication Date Title
IL217942A0 (en) Intravenous formulations of neurokinin-1 antagonist
PL2475738T3 (pl) Zastosowanie kompozycji trójskładnikowych
PL3158991T3 (pl) Preparaty bendamustyny
EP2438246A4 (en) CONSTRUCTION ASPECTS
IL215865B (en) Meloxicam formulation
ZA201106703B (en) Use of pharmaceutical compositions containing mesembrenone
ZA201108413B (en) Oral compositions of celecoxib
PL2442648T3 (pl) Preparaty neonikotynoidów niezawierające nmp
EP2648519A4 (en) NEW POLYMORPH OF NILOTINIB HYDROCHLORIDE
EP2552447A4 (en) STABLE PHARMACEUTICAL COMPOSITION OF IMATINIB
PL2624836T3 (pl) Kompozycje bepotastyny
EP2593087A4 (en) PARENTERAL FORMULATIONS OF ELACYTARABINE DERIVATIVES
ZA201003844B (en) Delivery of functional compounds
SI2407155T1 (sl) Preparati na osnovi inekalcitola
EP2780001A4 (en) SOLID ORAL ENTECAVIR COMPOSITIONS WITH FAST RELEASE
EP2543373A4 (en) PHARMACEUTICAL COMPOSITION OF LEVOAMLODIPINE COMPOUND
GB0922023D0 (en) Preparation of n-monofluoroalkyl compounds
PL2407159T3 (pl) Kompozycje farmaceutyczne olmesartanu
ZA201108374B (en) Methods of administration of thrombopoietin agonist compounds
GB201100786D0 (en) Pharmaceutical compositions of immunosuppressants
EP2536688A4 (en) STABLE DOSAGE FORMS OF LEVOMILNACIPRAN
ZA201200531B (en) Pharmaceutical composition of rifampicin
GB201407689D0 (en) Pharmaceutical compositions of antihypertensives
HU0900698D0 (en) Pharmaceutical compositions of enhanced stability
GB0908549D0 (en) Meloxicam compositions